试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-23
Treatment of Acute Pericarditis With Anakinra
编号:NCT03224585登记状态:提前终止企业 / 申办者:Virginia Commonwealth University
药物 / 成分:Anakinra、Placebo
登记的停止原因(原文):Study was terminated because dramatic benefits seen during the first 24 hours of drug administration combined with COVID restrictions on research activities suggested it was both unethical and unnecessary to complete the planned enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer
编号:NCT00003654登记状态:提前终止企业 / 申办者:UNICANCER
药物 / 成分:patent blue V dye、lymphangiography、radionuclide imaging、sentinel lymph node biopsy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
编号:NCT00159757登记状态:提前终止企业 / 申办者:Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
药物 / 成分:ziprazidone
登记的停止原因(原文):See Detailed Description for Termination Reason
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
编号:NCT00585312登记状态:提前终止企业 / 申办者:Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
药物 / 成分:Celecoxib、Placebo
登记的停止原因(原文):See termination reason in detailed description.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
编号:NCT00645229登记状态:提前终止企业 / 申办者:Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
药物 / 成分:Ziprasidone
登记的停止原因(原文):Please see Detailed Description for termination reason.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
编号:NCT00645515登记状态:提前终止企业 / 申办者:Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
药物 / 成分:Ziprasidone、Risperidone
登记的停止原因(原文):This study was terminated on November 20, 2003 because of poor recruitment. This study was not terminated due to safety/efficacy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial
编号:NCT01770340登记状态:提前终止企业 / 申办者:Kantonsspital Winterthur KSW
药物 / 成分:Radical prostatectomy with implantation of allograft、Radical prostatectomy without implantation of allograft
登记的停止原因(原文):Poor recruitment, Interim analysis: The rates of pts who reached primary and secondary endpoints were lower than expected.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)
编号:NCT02243124登记状态:提前终止企业 / 申办者:Eleos, Inc.
药物 / 成分:cenersen、Dexamethasone
登记的停止原因(原文):Company went out of business
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
编号:NCT02244112登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:Oprozomib、Midazolam
登记的停止原因(原文):Why study stopped revised to "A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ009 was halted
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-02-21
Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures
编号:NCT02679560登记状态:提前终止企业 / 申办者:Ian Elliott Brown
药物 / 成分:Liposomal Bupivacaine、Ropivacaine HCL
登记的停止原因(原文):Poor recruitment
查看官方原始记录 ↗